Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced the appointment of Helen S. Kim, MBA, to its Board of Directors.
September 1, 2022
· 3 min read
